Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 457
Filter
1.
Dent Med Probl ; 61(3): 439-446, 2024.
Article in English | MEDLINE | ID: mdl-38916079

ABSTRACT

Periodontal mechanical debridement is the most common therapy for the treatment of periodontitis. However, depending on the severity of the disease, mechanical debridement has been recommended in combination with systemic antibiotics. In this study, we performed an overview of systematic reviews using the Friendly Summaries of Body of Evidence using Epistemonikos (FRISBEE) methodology on the effectiveness and safety of mechanical debridement combined with amoxicillin and metronidazole compared to mechanical debridement alone for the treatment of chronic periodontitis. We conducted a systematic search of the Epistemonikos database, extracted data from 10 systematic reviews and re-analyzed data from 23 primary studies to generate a summary of findings (SoF) table. We used RevMan 5.3 and GRADEpro for data analysis and data presentation. The following outcomes were analyzed: probing depth (mean difference (MD): 0.07 mm); clinical attachment level (MD: 0.04 mm); bleeding on probing (MD: 5.06%); and suppuration (MD: 0.31%). There was no evidence of a clinically relevant benefit of periodontal mechanical debridement therapy combined with amoxicillin and metronidazole compared to periodontal mechanical debridement therapy alone for the treatment of chronic periodontitis in the studied periodontal outcomes.


Subject(s)
Amoxicillin , Anti-Bacterial Agents , Chronic Periodontitis , Metronidazole , Periodontal Debridement , Humans , Amoxicillin/therapeutic use , Amoxicillin/administration & dosage , Anti-Bacterial Agents/therapeutic use , Chronic Periodontitis/therapy , Chronic Periodontitis/drug therapy , Combined Modality Therapy , Metronidazole/therapeutic use , Metronidazole/administration & dosage , Periodontal Debridement/methods
2.
Microbiol Spectr ; 12(8): e0040124, 2024 Aug 06.
Article in English | MEDLINE | ID: mdl-38916348

ABSTRACT

The aim of the present study was first to isolate Helicobacter pylori from gastric biopsy specimens and to test their antibiotic susceptibility. Second, it was to evaluate the efficacy of the standard triple therapy from patients of the west central region of Colombia. H. pylori positive patients received standard triple therapy with proton pump inhibitor (PPI) (40 mg b.i.d.), clarithromycin (500 mg b.i.d.), and amoxicillin (1 g b.i.d.) for 14 days. Thereafter, antibiotic susceptibility of the isolates was assessed by E-Test. From 94 patients enrolled, 67 were positive for H. pylori by histology or culture. Overall resistance to metronidazole, levofloxacin, rifampicin, clarithromycin, and amoxicillin was 81%, 26.2%, 23.9%, 19%, and 9.5%, respectively. No resistance was found for tetracycline. A total of 54 patients received standard triple therapy, 48 attended follow-ups testing, and of them, 30 had resistance test reports. Overall eradication rate was 81.2%. Second-line treatment was given to eight patients, four of whom were followed up with a 13C urea breath test (UBT) and remained positive for H. pylori. Eradication was significantly higher in patients with clarithromycin susceptible than in resistant strains (95.6% vs 42.8% P = 0.001). The updated percentages of resistance to clarithromycin in this geographical area had increased, so this value must be considered when choosing the treatment regimen.IMPORTANCEAntibiotic resistance in Helicobacter pylori has increased worldwide, as has resistance to multiple antimicrobials (MDRs), which seriously hampers the successful eradication of the infection. The ideal success rate in eradicating H. pylori infection (≥90%) was not achieved in this study (81.2%). This is the first time that MDR is reported (14.3%) in the region; the resistance to clarithromycin increased over time (3.8%-19%), and levofloxacin (26.2%) and rifampicin (23%) resistant isolates were detected for the first time. With these results, strain susceptibility testing is increasingly important, and the selection of treatment regimen should be based on local antibiotic resistance patterns.


Subject(s)
Amoxicillin , Anti-Bacterial Agents , Clarithromycin , Drug Therapy, Combination , Helicobacter Infections , Helicobacter pylori , Microbial Sensitivity Tests , Humans , Helicobacter pylori/drug effects , Helicobacter pylori/isolation & purification , Helicobacter pylori/genetics , Colombia , Helicobacter Infections/drug therapy , Helicobacter Infections/microbiology , Male , Female , Middle Aged , Anti-Bacterial Agents/therapeutic use , Anti-Bacterial Agents/pharmacology , Adult , Clarithromycin/pharmacology , Clarithromycin/therapeutic use , Amoxicillin/therapeutic use , Amoxicillin/pharmacology , Aged , Proton Pump Inhibitors/therapeutic use , Drug Resistance, Bacterial , Young Adult , Metronidazole/therapeutic use , Metronidazole/pharmacology , Levofloxacin/pharmacology , Levofloxacin/therapeutic use , Treatment Outcome
3.
Rev. cuba. estomatol ; 60(4)dic. 2023.
Article in Spanish | LILACS, CUMED | ID: biblio-1550856

ABSTRACT

Objetivo: Comparar el efecto de antibióticos pediátricos sobre la microdureza superficial del esmalte dental en dientes bovinos. Métodos: Se realizó un estudio in vitro en 60 dientes bovinos no cariados. Se sumergieron 15 dientes en cada grupo de cuatro soluciones (amoxicilina, amoxicilina + ácido clavulánico, eritromicina y saliva artificial) durante 1 minuto tres veces al día durante 7 y 14 días. Se midió la microdureza de la superficie del esmalte al inicio, a los7 y 14 días de exposición a los antibióticos. Resultados: La microdureza superficial del esmalte de los dientes de los grupos de antibióticos pediátricos se redujo después de 7 y 14 días de exposición con diferencia significativa (p < 0,001), respecto a la microdureza inicial. Además, en el grupo expuesto a saliva artificial no hubo diferencia significativa (p = 0,097) en los diferentes tiempos de evaluación. Conclusiones: Se concluye que los antibióticos pediátricos afectan la microdureza del esmalte, siendo la eritromicina la que mayor disminución generó a los 14 días de exposición(AU)


Objective: To compare the effect of pediatric antibiotics on the superficial microhardness of dental enamel in bovine teeth. Methods: An in vitro study was carried out on 60 non carious bovine teeth. Fifteen teeth were immersed in each group of four solutions (amoxicillin, amoxicillin + clavulanic acid, erythromycin and artificial saliva) for 1 minute three times a day for 7 and 14 days. Enamel surface microhardness was measured at baseline, 7 and 14 days of antibiotic exposure. Results: The enamel surface microhardness of the teeth of the pediatric antibiotic groups was reduced after seven and 14 days of exposure with significant difference (p < 0.001), with respect to the initial microhardness. In addition, in the group exposed to artificial saliva there was no significant difference (p = 0.097) at the different evaluation times. Conclusions: It is concluded that pediatric antibiotics affect enamel microhardness and erythromycin generated the greatest decrease at 14 days of exposure(AU)


Subject(s)
Humans , Child , Amoxicillin/therapeutic use , Anti-Bacterial Agents/administration & dosage
5.
J Oral Implantol ; 49(5): 537-543, 2023 Oct 01.
Article in English | MEDLINE | ID: mdl-37776244

ABSTRACT

Routine use of antibiotics for dental implant installation is widely applied in dental practice to prevent postoperative infection and implant loss. However, the effectiveness and necessity of such protocols have not been consensual in the literature. This study aimed to evaluate the effect of antibiotic prophylaxis on survival of dental implants placed in clinically healthy patients by unexperienced operators. A double-blind, randomized, placebo-controlled trial was conducted. Ninety patients who received between 2 and 4 dental implants by unexperienced operators were enrolled in this study. Patients were randomly allocated in 2 groups. For the antibiotic group (n = 47), patients received 1 g of preoperative amoxicillin; in the placebo group (n = 43), patients received preoperative placebo administration. Each patient was evaluated preoperatively, 2 days, and 7 days postoperatively. Factors evaluated were mouth opening amplitude, assessment of referred pain through a visual analogue scale, and characteristic signs of infection (presence of fistula, ulceration in the surgical wound, tissue necrosis at the edges of the wound, dehiscence of the surgical flap, and presence of purulent exudate in the surgical wound). Implant survival was evaluated until 90 days postsurgical procedure. Results showed that there were no statistically significant differences in postoperative healing, swelling, and pain. However, more loss of dental implants was observed in the placebo group (14.9% vs 2.3%). Use of antibiotic prophylaxis reduced implant loss that was previously placed by unexperienced operators.


Subject(s)
Dental Implants , Surgical Wound , Humans , Amoxicillin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Antibiotic Prophylaxis/methods , Surgical Wound/drug therapy , Surgical Wound Infection/prevention & control , Surgical Wound Infection/drug therapy , Double-Blind Method
6.
Rev Gastroenterol Peru ; 43(2): 116-119, 2023.
Article in Spanish | MEDLINE | ID: mdl-37597225

ABSTRACT

Our objective is to determine the effectiveness of a therapeutic regimen for helicobacter pylori that includes a proton pump inhibitor, doxycycline, furazolidone and bismuth in our location. We carried out a retrospective study, non-randomized, in a private hospital in Lima, Peru. Patients with biopsy and/or rapid urease test proven helicobacter pylori infection after an endoscopy, from January 2017 to October 2022 were included. They received the therapeutic regimen of the study or an alternative triple regimen with a proton pump inhibitor, amoxicillin and levofloxacin and were followed with a urea breath test within 1 to 6 months upon completion of therapy. The quadruple therapy with furazolidone obtained success in 117/122 cases (95.9%) while the triple therapy with levofloxacin only in 5/16 (31.2%) when used for 7 days and 22/38 (57.9%) when used for 10 days, a statistically significant difference with p<0.001. Conclusion: Quadruple therapy with furazolidone reached high effectiveness in our location, while triple therapy with levofloxacin was not an acceptable alternative.


Subject(s)
Helicobacter Infections , Helicobacter pylori , Humans , Bismuth/therapeutic use , Doxycycline/therapeutic use , Proton Pump Inhibitors/therapeutic use , Helicobacter Infections/drug therapy , Furazolidone/therapeutic use , Furazolidone/pharmacology , Anti-Bacterial Agents/therapeutic use , Levofloxacin/therapeutic use , Levofloxacin/pharmacology , Retrospective Studies , Drug Therapy, Combination , Amoxicillin/therapeutic use , Treatment Outcome
7.
Acta méd. costarric ; 65(1): 21-25, ene.-mar. 2023. graf
Article in Spanish | LILACS, SaludCR | ID: biblio-1527609

ABSTRACT

Resumen Objetivo: Este estudio tiene como objetivo principal determinar la respuesta al esquema de tratamiento de primera línea con triple terapia estándar (amoxicilina, claritromicina, omeprazol), para erradicación de Helicobacter pylori en una determinada población, para determinar si este esquema propuesto en guías internacionales es aún una opción adecuada para pacientes en una determinada región de Costa Rica. Métodos: Se realizó una búsqueda en el servicio de gastroenterología del Hospital San Francisco de Asís, Grecia, Alajuela, Costa Rica; de todos los pacientes con infección por Helicobacter pylori y que recibieron tratamiento de primera línea con triple terapia (amoxicilina, claritromicina y omeprazol) por 14 días, en el periodo comprendido entre febrero 2017 a febrero 2019, incluyendo para el análisis solamente en los que se contaba con una prueba confirmatoria posterior a tratamiento, ya fuera por antígeno fecal de H. pylori o biopsia convencional. Resultados: Se identificaron un total de 369 casos. El diagnóstico se realizó con biopsia en el 96,4% de los pacientes. La respuesta al tratamiento de primera línea se alcanzó en un 90.5% corroborada por antígeno fecal en el 92.1% de los casos. Conclusiones: Este estudio muestra que la terapia triple con amoxicilina, claritromicina e Inhibidor de bomba de protones por 14 días mantiene un adecuado nivel de eficacia. Sin embargo, hay que tomar en cuenta que estos datos son únicamente de un área de atracción determinada y puede que no reflejen la realidad de todo el país.


Abstract Aim: The main objective of this study is to determine the response to the firstline treatment regimen with triple standard therapy (amoxicillin, clarithromycin, omeprazole), to eradicate Helicobacter pylori in a certain population. The goal is to determine if the proposed regimen in international guidelines services is still a suitable option for patients in a certain region of Costa Rica. Methods: The study took place in San Francisco de Asís Hospital, Grecia, Alajuela, Costa Rica. All patients with a Helicobacter pylori infection that were given first- line treatment with triple therapy (amoxicillin, clarithromycin and omeprazole) for its eradication for 14 days, in the period between February of 2017 and February of 2019, were included in the study. Results: A total of 369 cases were identified. The diagnosis was made with biopsy in 96.4% of patients. Response to first-line treatment was achieved in 90.5% corroborated by fecal antigen in 92.1% of all cases. Conclusions: This study shows that triple therapy with amoxicillin, clarithromycin and omeprazole for 14 days maintains an adequate level of efficacy. However, it must be considered that these results are from a specific area and may not reflect the reality of the entire country.


Subject(s)
Humans , Male , Female , Omeprazole/therapeutic use , Helicobacter pylori/drug effects , Helicobacter Infections/epidemiology , Clarithromycin/therapeutic use , Amoxicillin/therapeutic use , Costa Rica , Drug Resistance, Bacterial
8.
J Periodontol ; 94(4): 498-508, 2023 04.
Article in English | MEDLINE | ID: mdl-35869939

ABSTRACT

BACKGROUND: Despite the body of evidence supporting the clinical benefits of metronidazole (MTZ) and amoxicillin (AMX) in the treatment of young patients with periodontitis, the microbiological outcomes of this antibiotic protocol have been less explored. This study evaluated the microbiological effects of adjunctive MTZ+AMX in the treatment of young patients with periodontitis. METHODS: Subjects with periodontitis Stages III or IV and ≤30 years old were randomly allocated to receive scaling and root planing (SRP) with placebo (n = 15) or with MTZ (400 mg) and AMX (500 mg) three times a day for 14 days (n = 15). Nine subgingival biofilm samples per subject (three samples from each probing depth (PD) category: ≤3, 4-6, and ≥7 mm) were collected at baseline and 3-, 6-, and 12-months post-treatment and individually analyzed for 40 bacterial species by checkerboard DNA-DNA hybridization. RESULTS: Thirty subjects (15/group) with mean ages 27.6 ± 3.5 (control) and 26.8 ± 3.9 (test) were included. At 12 months post-therapy, the antibiotic group harbored lower proportions of red complex (1.3%) than the placebo group (12.5%) (p < 0.05). SRP + MTZ+AMX was more effective than mechanical treatment in reducing levels/proportions of several pathogens and increasing proportions of Actinomyces species (p < 0.05). Levels/proportions of Aggregatibacter actinomycetemcomitans were only reduced in the antibiotic group (p < 0.05). This group also exhibited greater reduction in the number of sites with PD ≥5 mm and higher percentage of subjects reaching the clinical end point for treatment (≤4 sites with PD ≥5 mm) than the control group (p < 0.05). CONCLUSION: SRP+MTZ+AMX allowed for establishing a long-term healthier subgingival biofilm community and periodontal clinical condition, than SRP only.


Subject(s)
Dental Plaque , Periodontitis , Humans , Young Adult , Adult , Metronidazole/therapeutic use , Amoxicillin/therapeutic use , Combined Modality Therapy , Dental Plaque/microbiology , Anti-Bacterial Agents/therapeutic use , Periodontitis/drug therapy , Dental Scaling/methods , Root Planing/methods , DNA/therapeutic use , Treatment Outcome
10.
J Periodontal Res ; 57(6): 1116-1126, 2022 Dec.
Article in English | MEDLINE | ID: mdl-36050890

ABSTRACT

OBJECTIVE: This study aimed to investigate the influence of smoking on clinical, microbiological and immunological parameters in young adult with stage III-IV Grade C periodontitis after full-mouth ultrasonic debridement (FMUD) associated with Amoxicillin and Metronidazole (AMX + MTZ), comparing smokers (PerioC-Y-Smk) with non-smokers (PerioC-Y-NSmk). MATERIALS AND METHODS: Fifteen PerioC-Y-NSmk and 14 PerioC-Y-Smk patients underwent FMUD associated with AMX + MTZ for 10 days. All parameters were collected at baseline and 3 and 6 months after treatment. Plaque index (PI), bleeding on probing (BoP), probing depth (PD), clinical attachment level (CAL)- the primary variable-, and gingival recession (GR) were clinically assessed. The impact of PI on CAL change at 6-month was verified by a regression analysis. Samples of the subgingival biofilm was collected for detection of levels of Aggregatibacter actinomycetemcomitans (A. actinomycetemcomitans), Porphyromonas gingivalis (P.gingivalis), Tannerella forsythia (T. forsythia), and Fusobacterium nucleatum ssp (F. nucleatum), and were analyzed by real-time qPCR; gingival crevicular fluid was collected for detection of levels of interleukin (IL)-1ß, IL-4, IL-6, IL-10, tumor necrosis factor (TNF)-α, and interferon (IFN)-γ, which were analyzed using an enzyme immunoassay. RESULTS: PerioC-Y-Smk had significantly higher PI, BOP, and GR at baseline compared to non-smokers (p < .05). PerioC-Y-Smk presented higher PD, CAL, and GR at 3 and 6 months (p < .05) compared with PerioC-Y-NSmk in the same periods; PI negatively affected CAL gain in PerioC-Y-NSmk at 6-month follow-up (p = .052) and did not impact on clinical response in PerioC-Y-Smk (p = .882). Lower levels of IFN-γ, IL1-ß, and IL-4 were observed at 3 months in the PerioC-Y-NSmk (p < .05) compared with PerioC-Y-Smk. Lower proportions of P. gingivalis were observed in PerioC-Y-NSmk at baseline and at 3 months (p < .05) and lower proportions of F. nucleatum were observed at 6 months, in the PerioC-Y-NSmk (p < .05). CONCLUSIONS: PerioC-Y-Smk presents an unfavorable clinical, microbiological, and immunological response after 3 and 6 months after FMUD associated with AMX + MTZ. CLINICAL RELEVANCE: Smoking worsens periodontal condition of young treated adults presenting stage III/IV Grade C periodontitis.


Subject(s)
Interleukin-4 , Periodontitis , Humans , Young Adult , Periodontitis/drug therapy , Gingival Crevicular Fluid , Amoxicillin/therapeutic use , Metronidazole/therapeutic use , Aggregatibacter actinomycetemcomitans , Porphyromonas gingivalis , Smoking/adverse effects , Follow-Up Studies
11.
J Pediatr ; 251: 98-104.e5, 2022 12.
Article in English | MEDLINE | ID: mdl-35944719

ABSTRACT

OBJECTIVES: The objective of the study was to compare the antibiotic treatment failure and recurrence rates between antibiotic agents (amoxicillin, amoxicillin-clavulanate, cefdinir, and azithromycin) for children with uncomplicated acute otitis media (AOM). STUDY DESIGN: We completed a retrospective cohort study of children 6 months-12 years of age with uncomplicated AOM identified in a nationwide claims database. The primary exposure was the antibiotic agent, and the primary outcomes were treatment failure and recurrence. Logistic regression was used to estimate ORs, and analyses were stratified by primary exposure, patient age, and antibiotic duration. RESULTS: Among the 1 051 007 children included in the analysis, 56.6% were prescribed amoxicillin, 13.5% were prescribed amoxicillin-clavulanate, 20.6% were prescribed cefdinir, and 9.3% were prescribed azithromycin. Most prescriptions (93%) were for 10 days, and 98% were filled within 1 day of the medical encounter. Treatment failure and recurrence occurred in 2.2% (95% CI: 2.1, 2.2) and 3.3% (3.2, 3.3) of children, respectively. Combined failure and recurrence rates were low for all agents including amoxicillin (1.7%; 1.7, 1.8), amoxicillin-clavulanate (11.3%; 11.1, 11.5), cefdinir (10.0%; 9.8, 10.1), and azithromycin (9.8%; 9.6, 10.0). CONCLUSIONS: Despite microbiologic changes in AOM etiology, treatment failure and recurrence were uncommon for all antibiotic agents and were lower for amoxicillin than for other agents. These findings support the continued use of amoxicillin as a first-line agent for AOM when antibiotics are prescribed.


Subject(s)
Amoxicillin , Otitis Media , Child , Humans , Infant , Amoxicillin/therapeutic use , Azithromycin/therapeutic use , Cefdinir , Retrospective Studies , Acute Disease , Treatment Outcome , Anti-Bacterial Agents/therapeutic use , Otitis Media/drug therapy , Otitis Media/microbiology , Amoxicillin-Potassium Clavulanate Combination/therapeutic use
12.
Rev. med. Chile ; 150(8): 1000-1009, ago. 2022. tab, graf
Article in Spanish | LILACS | ID: biblio-1431862

ABSTRACT

BACKGROUND: The over prescription of antibiotics for acute respiratory infections is a major public health problem worldwide. Aim: To evaluate the frequency of prescription of antibiotics for non-pneumonia acute respiratory infections in private outpatient clinics in individuals without chronic diseases or immunosuppression. MATERIAL AND METHODS: All medical records of adult consultants in a national network of private ambulatory medical centers during May 2018 whose primary diagnosis corresponded to acute respiratory infections not pneumonia (ICD10) were identified and retrospectively analyzed, excluding those with chronic respiratory conditions or states of immunosuppression. RESULTS: Of the 38,072 consultants (aged 36 years, 63% women) who met this criterion, 54% (n = 20,499) received a prescription for at least one antibiotic. The diagnoses that most frequently received this prescription were acute bronchitis (28.7%), acute sinusitis (16.5%) and acute tonsillitis (16.2%). The most frequently prescribed antibiotic globally was azithromycin (37.4%), followed by amoxicillin (20.1%) and amoxicillin plus clavulanic acid (17.7%). Levofloxacin prescription reached 12.5% of total prescriptions. CONCLUSIONS: An antibiotic was prescribed in more than half of the non-pneumonia outpatient acute respiratory infections. Azithromycin was the most prescribed antibiotic, while levofloxacin exceeded 10% of prescriptions. These results reinforce the need to implement an antibiotic prescription surveillance system at the outpatient level.


Subject(s)
Humans , Male , Female , Adult , Respiratory Tract Infections/drug therapy , Respiratory Tract Infections/epidemiology , Anti-Bacterial Agents/therapeutic use , Outpatients , Drug Prescriptions , Practice Patterns, Physicians' , Acute Disease , Retrospective Studies , Azithromycin/therapeutic use , Levofloxacin/therapeutic use , Amoxicillin/therapeutic use
13.
Mitochondrion ; 66: 7-12, 2022 09.
Article in English | MEDLINE | ID: mdl-35843591

ABSTRACT

Antibiotics may trigger alterations in mitochondrial function, which has been explored in cells culture, and in animal model of sepsis. This study sought to evaluate whether antibiotic therapy affects mitochondrial bioenergetics in a 68-patients clinical study. We studied mitochondrial respiratory rates at two time points: the first day of antibiotic administration and three days after. The Δbasal, ΔCI, ΔCII respiration, and ΔBCE respiratory rates were not different between patients administered with polymyxin, vancomycin, amoxicillin-clavulanate, and azithromycin compared to those who were not administered. Specific beta-lactams are associated with specific modifications in mitochondrial respiratory endpoints - patients who used meropenem had higher delta C2 values compared to those who did not (p = 0.03). Patients who used piperacillin-tazobactam had lower delta C1 (p = 0.03) values than those who did not, but higher delta C2 values (p = 0.02). These mitochondrial metabolic signatures in isolated lymphocytes challenges the proposed effects of antibiotics in mitochondrial bioenergetics of cell cultures, but at current status have an uncertain clinical significance.


Subject(s)
Shock, Septic , Amoxicillin/therapeutic use , Anti-Bacterial Agents , Azithromycin/therapeutic use , Clavulanic Acid/therapeutic use , Energy Metabolism , Humans , Lymphocytes , Meropenem/therapeutic use , Mitochondria , Piperacillin, Tazobactam Drug Combination/therapeutic use , Polymyxins/therapeutic use , Prospective Studies , Shock, Septic/drug therapy , Vancomycin/therapeutic use , beta-Lactams/therapeutic use
14.
Dent Traumatol ; 38(5): 397-409, 2022 Oct.
Article in English | MEDLINE | ID: mdl-35662418

ABSTRACT

BACKGROUND/AIM: The evidence for any benefit of systemic antibiotic therapy on pulp survival following extrusive luxation and avulsion is inconclusive. The aim of this study was to evaluate the effect of systemic antibiotic therapy with amoxycillin and tetracycline for 7 days on different aspects of dental pulp repair in a murine model. MATERIAL AND METHODS: The right maxillary incisor of 180 4 to 8-week-old male Wistar rats underwent extrusive luxation or avulsion. The animals were then treated with saline solution (control), tetracycline, or amoxicillin administered intra-gastrically for 7 days, and euthanized at 7, 15, and 30 days post-operatively. The layer of odontoblast cells, reparative dentin deposition, Hertwig's epithelial root sheath, pulp necrosis, and periapical inflammatory infiltrate were histomorphologically analyzed and scored. Mann-Whitney, Kruskal-Wallis, and Dunn tests were used to compare mean scores for the different procedures, treatments, and times (p ≤ .05). RESULTS: Significant differences were observed between luxated and avulsed teeth (p < .05). In luxated teeth, no differences were observed among treatments and times, except for more tertiary dentin deposition in the coronal third with the use of tetracycline compared with amoxicillin at 15 days (p < .05). In avulsed teeth, higher scores for the layer of odontoblast cells and lower scores for periapical inflammatory infiltrate at 7 days and pulp necrosis at 7 and 15 days were observed in the amoxicillin group compared to the saline and tetracycline groups (p < .05). At 30 days, however, no differences were observed among treatments. CONCLUSIONS: The use of systemic antibiotic therapy with tetracycline or amoxicillin for 7 days did not contribute to pulp repair following extrusive luxation or avulsion in rats. However, the results warrant further research into the use of amoxicillin for a more extended period of time in cases of avulsion.


Subject(s)
Dental Pulp Necrosis , Tooth Avulsion , Amoxicillin/pharmacology , Amoxicillin/therapeutic use , Animals , Anti-Bacterial Agents/pharmacology , Dental Pulp , Dental Pulp Necrosis/drug therapy , Male , Mice , Rats , Rats, Wistar , Tetracyclines , Tooth Avulsion/therapy
15.
Int J Gynaecol Obstet ; 159(1): 56-64, 2022 Oct.
Article in English | MEDLINE | ID: mdl-34995367

ABSTRACT

BACKGROUND: During pregnancy, urinary infections are an important cause of maternofetal morbidity and mortality and may lead to several complications. OBJECTIVE: To verify whether the use of antibiotic therapy in a single dose when compared with multiple doses in lower tract urinary infections during pregnancy is effective to obtain microbiologic cure. SEARCH STRATEGY: Online databases were searched. Keywords used were "single-drug dose", "antibiotic", "fosfomycin", "amoxicillin", "trimethoprim", "pregnancy", and "urinary tract infection". SELECTION CRITERIA: Studies were included if they were randomized controlled trials, the population was pregnant woman, microbiologic cure was attained, and one of the treatment groups received single-dose antibiotic therapy. DATA COLLECTION AND ANALYSIS: Preselected studies have been independently read by pairs, and data were extracted according to a predetermined sheet. The Cochrane tool was used for the risk of bias. MAIN RESULTS: A total of 1063 women from nine studies were included. The primary outcome was the microbiologic cure attested by urine culture. When compared with the multiple-day use of antibiotics, the single-dose treatment has shown statistically similar results in reaching culture cure (odds ratio 1.02, 95% confidence interval 0.73-1.44). CONCLUSION: The current study has shown that the use of single-dose treatment for lower tract urinary infections during pregnancy can be recommended, especially using fosfomycin. SYSTEMATIC REVIEW REGISTRATION: This review has not been registered.


Subject(s)
Urinary Tract Infections , Amoxicillin/therapeutic use , Anti-Bacterial Agents , Female , Humans , Randomized Controlled Trials as Topic , Urinary Tract Infections/drug therapy
16.
Gastroenterol Hepatol ; 45(7): 515-523, 2022.
Article in English, Spanish | MEDLINE | ID: mdl-34890721

ABSTRACT

INTRODUCTION: Helicobacter pylori infection affects approximately 70% of the Chilean population. It is a public health problem whose eradication treatment is part of the explicit health guarantees in Chile. OBJECTIVES: Characterize the most widely used H. pylori first-line eradication therapies in our environment and evaluate their efficacy. METHODS: A retrospective observational study was carried out where, in patients with certified H. pylori infection, the eradication therapy indicated by the treating physician, its efficacy, adherence and adverse effects, in addition to the eradication certification method used, were evaluated. RESULTS: 242 patients and 4 main therapies were analyzed: standard triple therapy, dual therapy, concomitant therapy, and bismuth quadruple therapy. Eradication rates of 81.9% (95% CI 74.44-87.63), 88.5% (95% CI 73.13-95.67), 93.7% (95% CI 78.07-98.44) and 97.6% (95% CI 84.81-99.67) were observed respectively, with concomitant therapy (RR: 1.14; 95% CI 1.01-1.29; p=.028) and quadruple therapy with bismuth (RR: 1.19; 95% CI 1.09-1.31; p<.001) being significantly more effective than standard triple therapy. Regarding the rate of reported adverse effects, it was 58.5% (95% CI 50.66-65.92), 35.4% (95% CI 24.6-48.11), 22.9% (95% CI 81-37.14) and 63.4% (95% CI 47.8-76.64), having the dual and concomitant therapy significantly fewer adverse effects compared with standard therapy. CONCLUSIONS: Quadruple therapies are superior to standard triple therapy and should be considered as first-line treatment in Chile. Dual therapy is promising. More studies will be required to determine which therapies are most cost-effective.


Subject(s)
Helicobacter Infections , Helicobacter pylori , Amoxicillin/therapeutic use , Anti-Bacterial Agents/adverse effects , Bismuth/therapeutic use , Chile , Drug Therapy, Combination , Helicobacter Infections/drug therapy , Humans , Proton Pump Inhibitors/therapeutic use
17.
Rev Gastroenterol Peru ; 42(3): 151-162, 2022.
Article in Spanish | MEDLINE | ID: mdl-36746495

ABSTRACT

Helicobacter pylori infection is quite common worldwide and is associated with gastric adenocarcinoma. The high rates of resistance found in Latin American countries justify the investigation of local resistance rates, which could improve the therapeutic approach and eradication rates. The objective is to evaluate the prevalence of resistance in Peru of Helicobacter pylori to commonly used antibiotics. All studies in the Peruvian population that revealed rates of antibiotic resistance of Helicobacter pylori were included. A systematic literature search was conducted up to January 2021, using PubMed and other databases. For the group of patient studies with the EUCAST cut-off point, the resistance was as follows: Amoxicillin 14% (95% CI: 6-25), Clarithromycin 43% (95% CI: 30-57), Metronidazole 58% (95% CI: 22-90) and 51% Quinolones (95% CI: 38-64). For the EUCAST cut-off group of sample studies, the following: Amoxicillin 57% (95% CI: 51-63), Clarithromycin 35% (95% CI 30-41), Metronidazole 67% (95% CI: 62-72) and 4% Tetracycline (95% CI: 2-7). A high antibiotic resistance of Helicobacter pylori was found in most of the groups studied, although with heterogeneity between the studies. The rate of resistance to tetracyclines was low and the studies were shown to be homogeneous.


Subject(s)
Helicobacter Infections , Helicobacter pylori , Humans , Helicobacter Infections/drug therapy , Helicobacter Infections/epidemiology , Clarithromycin/therapeutic use , Metronidazole/therapeutic use , Peru/epidemiology , Prevalence , Drug Resistance, Bacterial , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Amoxicillin/therapeutic use , Microbial Sensitivity Tests
18.
Rev Med Chil ; 150(8): 1000-1009, 2022 Aug.
Article in Spanish | MEDLINE | ID: mdl-37358147

ABSTRACT

BACKGROUND: The over prescription of antibiotics for acute respiratory infections is a major public health problem worldwide. AIM: To evaluate the frequency of prescription of antibiotics for non-pneumonia acute respiratory infections in private outpatient clinics in individuals without chronic diseases or immunosuppression. MATERIAL AND METHODS: All medical records of adult consultants in a national network of private ambulatory medical centers during May 2018 whose primary diagnosis corresponded to acute respiratory infections not pneumonia (ICD10) were identified and retrospectively analyzed, excluding those with chronic respiratory conditions or states of immunosuppression. RESULTS: Of the 38,072 consultants (aged 36 years, 63% women) who met this criterion, 54% (n = 20,499) received a prescription for at least one antibiotic. The diagnoses that most frequently received this prescription were acute bronchitis (28.7%), acute sinusitis (16.5%) and acute tonsillitis (16.2%). The most frequently prescribed antibiotic globally was azithromycin (37.4%), followed by amoxicillin (20.1%) and amoxicillin plus clavulanic acid (17.7%). Levofloxacin prescription reached 12.5% of total prescriptions. CONCLUSIONS: An antibiotic was prescribed in more than half of the non-pneumonia outpatient acute respiratory infections. Azithromycin was the most prescribed antibiotic, while levofloxacin exceeded 10% of prescriptions. These results reinforce the need to implement an antibiotic prescription surveillance system at the outpatient level.


Subject(s)
Anti-Bacterial Agents , Respiratory Tract Infections , Adult , Humans , Female , Male , Anti-Bacterial Agents/therapeutic use , Azithromycin/therapeutic use , Outpatients , Retrospective Studies , Levofloxacin/therapeutic use , Practice Patterns, Physicians' , Respiratory Tract Infections/drug therapy , Respiratory Tract Infections/epidemiology , Amoxicillin/therapeutic use , Drug Prescriptions , Acute Disease
19.
Helicobacter ; 26(6): e12853, 2021 Dec.
Article in English | MEDLINE | ID: mdl-34528337

ABSTRACT

OBJECTIVES: Helicobacter pylori (H. pylori) is the primary cause of gastric cancer and eradication in healthy adults has proven effective in decreasing cancer incidence. H. pylori is acquired largely in early childhood, however, the benefits of eradication in children are controversial. We aimed to determine the effect of H. pylori eradication on clinical and laboratory markers associated with gastric damage in apparently healthy school-aged children. METHODS: This was a pilot non-blinded trial including 61 children persistently infected with H. pylori who were randomized to eradication/no treatment and followed for at least 12 months, evaluating clinical and blood markers (Pepsinogen I (PGI) and II (PGII) determined by ELISA) associated with gastric damage. The treatment consisted of a sequential scheme including 7 days of omeprazole + amoxicillin followed by 7 days of omeprazole + clarithromycin + metronidazole; adherence and tolerance were surveyed. Eradication rates were assessed by stool antigen detection or urea breath test 1 month following treatment every 4 months thereafter to detect reinfection. RESULTS: Eradication occurred in 30/31 treated children (median age: 8.8, range: 7.9-10.8) and in 0/30 non-treated controls (median age: 8.6, range: 7.9-11) (p < .001). Treatment was associated with mild transient symptoms (altered taste, nocturnal upper abdominal pain, nausea, and diarrhea). Baseline frequency of symptoms was low and eradication did not change symptoms compared to controls. PGI, PGII, and anti-H. pylori seropositivity were similar in both groups at baseline and significantly decreased only in eradicated patients; PGI (92.5 vs. 74.4, p < .001), PGII (15.2 vs. 8.9, p < .001) levels, and frequency of anti-H. pylori seropositivity (100 vs. 68%, p < .001) respectively. Four eradicated children (13%) were reinfected during follow-up. CONCLUSIONS: H. pylori eradication therapy in apparently asymptomatic school-aged children was well tolerated and associated with decreased serum PGI and PGII levels. Future studies should expand on the middle-long-term effect of early H. pylori eradication, especially on preventing gastric cancer.


Subject(s)
Anti-Ulcer Agents , Helicobacter Infections , Helicobacter pylori , Adult , Amoxicillin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Anti-Ulcer Agents/therapeutic use , Biomarkers , Child , Child, Preschool , Clarithromycin/therapeutic use , Drug Therapy, Combination , Helicobacter Infections/diagnosis , Helicobacter Infections/drug therapy , Humans , Laboratories , Pepsinogen C , Schools
20.
Andes Pediatr ; 92(1): 93-98, 2021 Feb.
Article in English, Spanish | MEDLINE | ID: mdl-34106188

ABSTRACT

INTRODUCTION: Fusobacterium nucleatum is an anaerobic bacillus that is part of the oral microbiota and dental pla que. This can cause local and potentially remote infections, which are exceptional in pediatrics. Ob jective: To present the case of a patient with lung injury with chest wall invasion by Fusobacterium nucleatum. CLINICAL CASE: An 11-year-old female immunocompetent patient who consulted due to a two-week history of cough, night sweats, without fever or weight loss, and increased volume at the left spleen thoracic level. There was no history of chest wall trauma or travel outside the country. Two weeks before the onset of symptoms, she was treated for dental caries. Imaging studies and CT scan showed left spleen pneumonia, which invades the pleura and the chest wall. A minimal thoracotomy was performed, releasing a thick, foul-smelling liquid. The studies for common germs and tubercu losis were negative. Hematology ruled out tumor lesions. The anaerobic study reported the develo pment of Fusobacterium nucleatum. The patient was treated with penicillin followed by amoxicillin presenting good clinical and radiological responses. The dental procedure was suspected as the cause of infection. CONCLUSIONS: Fusobacterium nucleatum can occasionally cause remote or extra-oral in fections in immunocompetent patients, such as pneumonia with chest wall invasion, therefore it is necessary to bear it in mind.


Subject(s)
Fusobacterium Infections , Fusobacterium nucleatum/isolation & purification , Pneumonia, Bacterial/microbiology , Amoxicillin/therapeutic use , Anti-Bacterial Agents/therapeutic use , Child , Dental Caries/complications , Dental Caries/therapy , Female , Fusobacterium Infections/diagnostic imaging , Fusobacterium Infections/drug therapy , Fusobacterium Infections/surgery , Humans , Penicillins/therapeutic use , Pneumonia, Bacterial/diagnostic imaging , Pneumonia, Bacterial/drug therapy , Pneumonia, Bacterial/surgery , Thoracic Wall/microbiology , Thoracotomy
SELECTION OF CITATIONS
SEARCH DETAIL